Stan Polovets | Chairman of the Board

Mr. Polovets joined the board of Anchiano in April 2020. A graduate of Stanford Graduate School of Business, he also currently serves as a member of the Board of Overseers of New York University (NYU) Tandon School of Engineering, NYU President’s Global Council, and the Council on Foreign Relations.

Mr. Polovets previously served as CEO of AAR, a private equity firm with a global energy portfolio valued in excess of $25 billion, and as Sr. Vice President at TNK-BP, one of the world’s largest oil companies. Mr. Polovets also held management, advisory, M&A and various financial positions at ExxonMobil, KPMG, TNK-BP and EY.

Mr. Polovets brings extensive board experience to Anchiano. Prior to joining its board, Mr. Polovets served as Lead Non-Executive Director of Clal Industries, Lead Independent Director of L1 Energy, Lead Independent Director at Taavura, member of the Board of Overseers at Stanford University’s Hoover Institution, Chairman for Eastern Europe at Edelman, and director at oil companies Slavneft and TNK-BP.

He is a co-founder and chairman of The Genesis Prize Foundation, a prominent international philanthropic group.

Andrew Fine | Chief Financial Officer

Mr. Fine has served as our Chief Financial Officer since July 2020. Mr. Fine has over 20 years of experience in executive financial and operational roles and is currently Co-Managing Director at Line Consulting Ltd. Mr. Fine previously held roles as Chief Financial Officer at Seeking Alpha, ScaleMP and Freightos , leading finance and operations for the companies’ global activities.  Mr. Fine holds a BA and an MBA from the Hebrew University of Jerusalem.

Salar Roshan | Vice President, Head of Business Development

Mr. Roshan has served as our Head of Business Development since May 2019. Mr. Roshan leads the development of strategic partnerships and spearheaded the licensing transaction surrounding our pan-RAS and PDE10/β-catenin programs. Mr. Roshan joined Anchiano Therapeutics from Curis, Inc., an anti-cancer biotechnology company, where he served as Head of Corporate Development and was responsible for overseeing all aspects of the company’s corporate and business development strategy. Prior to that, he led the partial spin-off of the R&D division of Baxter Biosciences into Baxalta. While at Baxalta, he was also responsible for several product launches and oversaw valuation and long range planning for the hemophilia portfolio, which grossed roughly $4 billion in annual sales prior to Baxalta’s merger with Shire PLC. Mr. Roshan has also held roles of increasing responsibility at Ironwood Pharmaceuticals, Takeda US, Millennium Pharmaceuticals, and Genzyme. Mr. Roshan received his M.Sc. in finance and his M.B.A. from Kelley School of Business at Indiana University, and his B.Sc. in biotechnology from Northeastern University.